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Morgan Ye1, Marcella Warner1, Paolo Mocarelli2, Paolo Brambilla2 and Brenda Eskenazi1*
Abstract
Background: 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is a toxic environmental contaminant that can
bioaccumulate in humans, cross the placenta, and cause immunological effects in children, including altering their
risk of developing allergies. On July 10, 1976, a chemical explosion in Seveso, Italy, exposed nearby residents to a
high amount of TCDD. In 1996, the Seveso Women’s Health Study (SWHS) was established to study the effects of
TCDD on women’s health. Using data from the Seveso Second Generation Health Study, we aim to examine the
effect of prenatal exposure to TCDD on the risk of atopic conditions in SWHS children born after the explosion.
Methods: Individual-level TCDD was measured in maternal serum collected soon after the accident. In 2014, we
initiated the Seveso Second Generation Health Study to follow-up the children of the SWHS cohort who were born
after the explosion or who were exposed in utero to TCDD. We enrolled 677 children, and cases of atopic
conditions, including eczema, asthma, and hay fever, were identified by self-report during personal interviews with
the mothers and children. Log-binomial and Poisson regressions were used to determine the association between
prenatal TCDD and atopic conditions.
Results: A 10-fold increase in 1976 maternal serum TCDD (log10TCDD) was not significantly associated with asthma
(adjusted relative risk (RR) = 0.93; 95% CI: 0.61, 1.40) or hay fever (adjusted RR = 0.99; 95% CI: 0.76, 1.27), but was
significantly inversely associated with eczema (adjusted RR = 0.63; 95% CI: 0.40, 0.99). Maternal TCDD estimated at
pregnancy was not significantly associated with eczema, asthma, or hay fever. There was no strong evidence of
effect modification by child sex.
Conclusions: Our results suggest that maternal serum TCDD near the time of explosion is associated with lower
risk of eczema, which supports other evidence pointing to the dysregulated immune effects of TCDD.
Keywords: Dioxin, TCDD, Tetrachlorodibenzo-p-dioxin, Allergy, Asthma, Atopy, Seveso, Prenatal exposure
Background
Atopic conditions, including eczema, asthma, and hay
fever, are one of the leading causes of chronic illness
worldwide and are present in approximately 20% of the
population [1]. The prevalence of atopic diseases has
been increasing in the past few decades in both industri-
alized and developing countries [1]. One of the proposed
reasons for this is increased exposure to environmental
pollutants, as they can interfere with the immune system
and subsequently alter the risk of developing allergy and
asthma [2]. 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD),
a toxic chemical compound and a widespread environ-
ment contaminant, is produced as a byproduct of chem-
ical and industrial processes [2, 3]. Because TCDD is
highly lipophilic and has a relatively long half-life in
humans of 7–9 years, it can build up in the food chain
and accumulate in human fat tissues [4]. This is hazard-
ous because TCDD is a known human carcinogen and
potent endocrine disruptor, and has been shown to be
immunotoxic [5–7]. For example, a broad range of
immunotoxic effects have been observed in animal
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studies, including suppression of humoral and cell-
mediated immunity, impaired infection resistance, and po-
tential increased allergic sensitization [8–10]. Furthermore,
epidemiological studies have found that exposure to dioxin
or dioxin-like compounds is associated with dysregulated
immune responses related to inflammation and lower risk
of developing atopic conditions [11–15].
TCDD can cross the placental barrier [16] and impact
development of the fetus. Because the immune system de-
velops extensively during the fetal period, this is a critical
window of susceptibility to the effects of environmental
exposures. In experimental studies, prenatal and perinatal
exposure to TCDD suppresses immune function and exac-
erbates inflammatory conditions in the offspring [17–19].
However, research on the atopic effects of in utero expos-
ure to TCDD in humans is scarce and inconsistent [20–
30]. For example, in a Danish birth cohort study, maternal
serum levels of dioxin-like polychlorinated biphenyls
(PCB-118) was associated with children’s risk of developing
asthma [20], but not with allergic sensitization at 20 years
of age [21]. In contrast, birth cohort studies in Spain and
Slovakia did not find any associations in infants between
dioxin-like PCBs in maternal serum and wheeze [24] and
immunoglobulin E (IgE) levels [25], respectively. Overall,
results from these studies are inconsistent, with some stud-
ies reporting decreased risks [22, 23, 27, 31] and others in-
creased risk [20, 32].
Animal data also suggest that the immunomodulatory
effects of prenatal exposure to TCDD may be sex-
specific [19, 33]. However, few epidemiologic studies
have examined sex differences in allergic conditions, and
those that have showed inconsistent results. A study on
Canadian pregnant women found no evidence of sex
interaction between PCB-118 exposure and IgE levels in
offspring [28]. In contrast, a study in a Japanese cohort
of pregnant women found that dioxin concentrations in
maternal blood were negatively associated with IgE
levels in male infants, but not female infants [29]. When
allergic conditions were examined in this cohort, there
was a weak association with allergic symptoms in all in-
fants, but the risk of infections was higher in males [30].
On July 10, 1976, a chemical plant explosion in Seveso,
Italy, deposited approximately 30 kg of TCDD over the sur-
rounding area, which was divided into exposure zones (A,
B, and R) based on surface soil TCDD measurements. This
accident caused one of the highest residential exposures to
TCDD ever recorded [34]. A Seveso-based study found
that TCDD levels in adult residents of highly contaminated
and surrounding areas were negatively associated with im-
munoglobulin G (IgG) concentration, which suggests
TCDD may play a role in suppressing antibody production
[35]. In 1996, the Seveso Women’s Health Study (SWHS)
was initiated to examine the effects of TCDD exposure on
women’s health. SWHS is a historical cohort of women
living in Seveso or nearby areas when the explosion oc-
curred [36]. In 2014, the Seveso Second Generation Health
Study was initiated to follow-up the children of the SWHS
cohort who were born after the explosion or who were ex-
posed in utero to TCDD [37].
The aim of this study is to investigate the relationship
between prenatal exposure to TCDD and the risk of de-
veloping atopic conditions, including eczema, asthma,
and hay fever, in the Seveso second generation cohort.
We also aim to examine whether this relationship is
modified by the sex of the child.
Methods
Study population
Details of the SWHS and the Seveso Second Generation
Health Study are presented elsewhere [36, 37]. Briefly,
from 1996 to 1998, participants were recruited from the
female population residing in or near Seveso at the time
of explosion. Women were eligible if they were 40 years
old or younger, resided in the highest contaminated ex-
posure zones (A and B) on July 10, 1976, and had ar-
chived sera collected soon after the explosion in which
to measure TCDD. Of the eligible women, 981 (80%)
agreed to participate. From 2014 to 2016, we conducted
the Seveso Second Generation Health Study. Women
from the SWHS cohort and their children born after the
explosion were contacted. Eligible children included
those who were born to the SWHS cohort after July 10,
1976 who were 2 years or older at follow-up. Of 950
children, 16 were deceased and 9 were less than 2 years
old. Of the 925 eligible children, 677 children, 2 to
38 years of age and born to 438 mothers, were able to
be reached and agreed to participate (73%). For the ana-
lysis, we excluded one child under 18 years whose
mother was deceased and could not provide atopy-
related information for that child, leaving a final sample
of 676.
Procedures
Participation included written informed consent for
mothers and adult children (18+ years), oral assent for
children ages 7–12 years, and written assent for children
ages 13–17 years. The study was approved by the Insti-
tutional Review Boards of the participating institutions.
All participants underwent a brief medical exam includ-
ing blood pressure and anthropometry measurements, a
fasting blood draw, and a personal interview. All inter-
views were conducted in a private room at the Hospital
of Desio, Italy by trained nurse-interviewers who were
blinded to the mother’s TCDD levels and zone of resi-
dence. During the interviews, adult children were asked
about their reproductive and medical history, sociode-
mographic factors, and lifestyle characteristics. For chil-
dren under the age of 18, mothers were interviewed
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about their children. Atopy-related questions were adapted
from the International Study of Asthma and Allergies in
Childhood (ISAAC) questionnaire, which has been vali-
dated and standardized for international use [38]. Cases of
eczema, asthma, and hay fever were defined in two ways:
1) maternal or self-report of a diagnosis and/or symptoms
related to the conditions in the past 12 months, and 2) ma-
ternal or self-report of diagnosis only.
Diagnosis of eczema was determined by a positive an-
swer to the question, “Have you (has your child) ever
had eczema?” Additional symptom-based cases were de-
termined by positive answers to the following three
questions: “Have you (has your child) ever had an itchy
skin rash which was coming and going for at least 6
months?” If yes: “Have you (has your child) had this
itchy rash at any time in the past 12 months?” If yes:
“Has this itchy rash at any time affected any of the fol-
lowing places—the folds of the elbows, behind the knees,
in front of the ankles, under the buttocks or around the
neck, ears or eyes?”
Diagnosis of asthma was defined by a positive response
to the questions: “Has a doctor ever diagnosed you (your
child) with asthma?” or “Have you (has your child) ever
had asthma?” Additional symptom-based cases of
asthma were determined by a positive response to any of
the following during the previous 12 months: a) wheez-
ing or whistling in the chest; b) wheezing in the chest
during or after exercise or physical activity; and c) dry
cough at night, apart from a cough associated with a
cold or chest infection.
Diagnosis of hay fever was defined by a positive re-
sponse to the question, “Have you (has your child) ever
had hay fever?” Additional symptom-based cases were
determined by a positive response to the question, “In
the past 12 months, have you (has your child) had a
problem with sneezing or a runny or blocked nose when
you (your child) did not have a cold or the flu?”
Laboratory analysis
Details of the serum sample collection and TCDD
concentration measurements are presented elsewhere
[36, 39]. Maternal serum was collected soon after the ex-
plosion, and TCDD was measured in archived sera of
adequate volume by high-resolution gas chromatog-
raphy/high-resolution mass spectrometry methods at the
U.S. Centers for Disease Control and Prevention [40].
Non-detectable TCDD values were assigned one-half of
the detection limit. For this study, the median limit of
detection was 18.8 ppt, lipid-adjusted [41]. We estimated
maternal TCDD levels at pregnancy by extrapolation
from the nearest TCDD measurement in 1976, 1996, or
2008 using a first-order kinetic model with a half-life
that varies with initial dose, age, and covariates as de-
scribed previously [37, 42]. TCDD values are reported
on a lipid–weight basis as picograms per gram lipid or
parts per trillion (ppt) [43].
Statistical analysis
Prenatal TCDD exposure was examined in two ways: 1)
maternal initial (1976) serum TCDD level and 2) esti-
mated TCDD at pregnancy. Initial TCDD levels were
assessed to examine whether the primary dose perman-
ently impacts the woman’s endocrine or reproductive
system, resulting in heritable changes to her children.
TCDD levels at pregnancy were assessed to determine
whether direct fetal exposure during pregnancy impacts
the child’s atopic outcomes. Because of the skewed dis-
tribution of TCDD values, the maternal 1976 TCDD and
estimated TCDD at pregnancy variables were log10-
transformed for all analyses. Lipid-adjusted values of
TCDD concentration were analyzed as continuous vari-
ables. We fitted generalized additive models (GAMs) to
explore the shape of the relationships between the expo-
sures and outcomes. After transformation, the functions
were sufficiently linear and no further transformation
was necessary. Eczema, asthma, and hay fever were ana-
lyzed as binary variables (present vs. not present).
Potential covariates and confounders were identified a
priori based on a directed acyclic graph (DAG) and
existing literature on immune function, asthma, and al-
lergic diseases [44–48]. Maternal variables considered
included age at explosion and atopic history. Child-
based variables included maternal age at pregnancy, ma-
ternal body mass index (BMI) closest to birth year, ma-
ternal smoking during pregnancy, pre-term birth, season
of birth, breastfeeding duration, birth order, child sex,
child age, and primary wage earner education status. Po-
tential confounding variables from the DAG were con-
sidered for the regression models if they were
significantly associated with at least one of the outcome
variables in bivariate analyses (P < 0.2). Final models
were adjusted for maternal age at explosion, atopic his-
tory, age at pregnancy, BMI closest to birth year, and
smoking during pregnancy; child birth order, sex, and
age; and primary wage earner education at follow-up.
Multivariable log-binomial regressions were used to
examine the relationship between maternal TCDD levels
and the risk of eczema, asthma, and hay fever. For
models that were not able to converge using log-
binomial regressions, Poisson regressions with a robust
variance estimator were used [49]. These included the
models that examined the association between TCDD
estimated at pregnancy and hay fever defined by both
symptomology and diagnosis. For all of the models, a
clustered sandwich estimator of variance was used to ac-
count for non-independence of sibling clusters (n = 438
clusters) [50]. We also tested for effect modification by
child sex in all models by including a cross-product term
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between the exposures and child sex. In sensitivity ana-
lyses, we repeated final models for asthma, excluding
one person who self-reported a diagnosis of asthma, but
did not report that it was doctor diagnosed. We also re-
peated final models for eczema, excluding one child who
reported “don’t know” rather than “no” for self-report of
a diagnosis of eczema. All statistical analyses were con-
ducted using Stata, version 13 [51]. Statistical signifi-
cance was set to be P-values < 0.05, unless otherwise
specified. Interaction P-values < 0.2 were considered to
be significant.
Results
Demographic and selected characteristics of our study
sample are presented in Table 1. For the 438 mothers,
the average age at explosion was 14.7 (standard devi-
ation (SD) = ±8.0) years, and the average age at preg-
nancy was 29.8 (SD = ±5.1) years; 20.8% reported a
history of asthma or allergy. Of the 676 children, 7.5%
had mothers who were obese near the time of birth,
9.3% had mothers who smoked during pregnancy, 6.8%
were born pre-term, 31.4% were breastfed for five or
more months, 59.3% were first-born, and 50.3% were fe-
male. At interview, the average age of the children was
22.9 (SD = ±9.9) years, and 70.4% of the household pri-
mary wage earners had achieved an education of high
school or greater. The distribution of births for each
birth season was approximately equal (Table 1).
The median lipid-adjusted serum TCDD concentration
near the time of the explosion for the 438 mothers was
64.7 ppt (interquartile range (IQR): 29.9–179.0), and the
median estimated TCDD concentration at pregnancy
was 11.2 ppt (IQR: 5.3–29.9). Consistent with our previ-
ous report, mothers who were youngest at the time of
explosion had the highest median initial TCDD concen-
tration (Table 1) [39].
Among the 676 children with known atopy status,
there were 98 eczema, 152 asthma and 243 hay fever
cases from maternal and self-report of diagnosis or
symptoms. The average age at diagnosis was 10 years for
eczema (n = 53), 7 years for asthma (n = 77), and 11 years
for hay fever (n = 126). Compared to non-cases, children
with eczema were more likely to have mothers who had
a history of asthma or allergy. Females were less likely
than males to have asthma. Children who were first
born, had mothers with a history of asthma or allergy,
and lived with a primary wage earner who was less edu-
cated were more likely to have hay fever (data not
shown).
Table 2 presents the associations between maternal
1976 TCDD levels and eczema, asthma, and hay fever.
Maternal 1976 TCDD was not associated with eczema
(adjusted RR per 10-fold increase in TCDD = 0.93, 95%
CI: 0.69, 1.27). When we limited the analysis to cases
defined only by reported doctor diagnosis (n = 55), the
results showed a significant inverse association between
1976 TCDD and eczema (adjusted RR = 0.63, 95% CI:
0.40, 0.99) (Table 2). Maternal 1976 TCDD was not asso-
ciated with asthma or hay fever by either case definition.
Unadjusted results are presented in Additional file 1:
Table S1.
Table 3 presents the associations between TCDD esti-
mated at pregnancy and eczema, asthma, and hay fever.
We found no evidence of a significant association be-
tween TCDD estimated at pregnancy and eczema (ad-
justed RR per 10-fold increase in TCDD = 0.90, 95% CI:
0.60, 1.38), asthma (adjusted RR = 0.93, 95% CI: 0.65,
1.34), or hay fever (adjusted RR = 1.09, 95% CI: 0.90,
1.31). All associations remained non-significant when we
limited the samples to include cases defined by a diagno-
sis only (Table 3).
There was limited evidence of effect modification by
child sex on the relationship between maternal 1976
TCDD or TCDD estimated at pregnancy and atopic condi-
tions. Specifically, among the samples that included cases
defined by both a diagnosis and symptomatology, we found
no evidence of effect modification by child sex on maternal
1976 TCDD and eczema (p-interaction = 0.54) or asthma
(p-interaction = 0.72). However, there was evidence of ef-
fect modification by child sex for hay fever (p = 0.07) with
non-significantly increased risk among female children (ad-
justed RR = 1.20, 95% CI: 0.95, 1.52) but not male children
(adjusted RR = 0.91, 95% CI: 0.73, 1.13) (Table 2). However,
there was no evidence of effect modification by sex on
TCDD estimated at pregnancy and eczema (p-interaction
= 0.75), asthma (p-interaction = 0.34), or hay fever (p-inter-
action = 0.67) (Table 3). Similarly, among the samples that
included only diagnosis-based case definitions, we found
no evidence of effect modification by child sex on maternal
1976 TCDD or TCDD estimated at pregnancy and atopic
conditions (Tables 2 and 3).
In sensitivity analyses, we repeated the final models for
asthma, excluding the one asthma case that was not
doctor diagnosed, and also repeated the final models for
eczema, excluding one child who reported “don’t know”
for their condition status. The results were similar (data
not shown).
Discussion
In this analysis of children of mothers who were exposed
to TCDD in Seveso, Italy in 1976, we found no evidence
of an association between maternal 1976 serum TCDD
or TCDD estimated at pregnancy and asthma or hay
fever although there was a non-significantly higher risk
in females than males in some analyses. However, we ob-
served a significant inverse association between eczema
and initial 1976 TCDD, and a non-significant inverse
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relationship with eczema and TCDD estimated at preg-
nancy, with no strong evidence of differences by sex.
The decreased risk of eczema is consistent with three
previous studies. A study in the Netherlands found that
both prenatal and postnatal exposure to dioxin concen-
trations measured in breast milk had a non-significant
inverse relationship with eczema [31]. Two studies in
Norway also reported a non-significant inverse relation-
ship between maternal dietary exposure to dioxins and
dioxin-like polychlorinated biphenyls (PCBs) at the 22nd
week of gestation and the risk of eczema and itchiness
in the face and joints [22, 23].
However, in contrast to our null findings of TCDD
and asthma symptomatology and allergy, one of the
Norwegian studies found an increased risk of wheeze
[23], and a Japanese cohort study of 18-month olds
found an increased risk for maternal report of food aller-
gies associated with polychlorinated dibenzo-p-dioxins
(PCDD), polychlorinated dibenzofurans (PCDF), and
dioxin-like PCBs measured in maternal blood in the
third trimester [30]. While these two studies did find an
increased risk, the children in the Norwegian study were
one-year-old, and most wheeze symptoms subside when
children reach ages three to five [23], and the Japanese
study measured food allergies, which may be related to
food intolerance instead of the immune system or atopic
conditions [30]. On the other hand, a Dutch study of
four-year-olds found a decreased risk of asthma-related
symptoms associated with prenatal exposure to dioxin-
like PCBs [27], which persisted to school-age [26], but
there was no association found for total dioxin toxic
equivalents (TEQ). Another Dutch study of older chil-
dren with prenatal and postnatal exposure to dioxins
measured in the mother’s breast milk shortly after birth
also reported a decreased risk in allergies [31]. The levels
of dioxin are lower in these studies [27, 31] than in the
Table 1 Distribution of maternal 1976 serum TCDD levels (ppt,
lipid-adjusted) by maternal and child-based characteristics;
SWHS, Italy, 1976–2016
N (%) N = 676
children of 438
mothers
1976 Serum TCDD
(ppt) Median (IQR)
Maternal characteristics (n = 438)
Age at explosion (years)*
< 11 137 (31.3) 162.0 (57.8–327.0)
11–17 143 (32.7) 55.0 (26.7–111.0)
18+ 158 (36.1) 43.8 (22.0–99.5)
Atopic history
Yes 91 (20.8) 85.2 (35.0–222.0)
No 347 (79.2) 63.3 (29.1–166.0)
Age at pregnancy (years)
< 26 140 (20.7) 44.1 (21.0–103.5)
26–29 194 (28.7) 62.3 (29.6–160.0)
30–33 177 (26.2) 76.2 (34.4–214.0)
34+ 165 (24.4) 76.9 (37.5–214.0)
BMI (kg/m2) closest to birth year
< 25 (underweight/normal) 477 (70.6) 67.5 (30.8–185.0)
25–29 (overweight) 148 (21.9) 49.9 (23.7–164.0)
30+ (obese) 51 (7.5) 86.7 (28.4–162.0)
Smoking during pregnancy a
Yes 63 (9.3) 55.2 (20.7–109.0)
No 609 (90.1) 66.8 (30.2–185.0)
Child Characteristics (n = 676)
Pre-term birth (< 37 weeks)
Yes 46 (6.8) 90.2 (33.2–245.0)
No 630 (93.2) 64.3 (29.6–173.0)
Season of birth
Spring 174 (25.7) 55.5 (29.0–196.0)
Summer 167 (24.7) 66.8 (29.9–174.0)
Fall 171 (25.3) 66.7 (28.6–176.0)
Winter 164 (24.3) 72.6 (33.4–170.0)
Breastfeeding duration (months)
< 1 214 (31.7) 60.3 (28.6–150.0)
1–4 250 (37.0) 69.9 (30.6–173.0)
5+ 212 (31.4) 66.2 (34.4–212.0)
Birth order
1 401 (59.3) 70.0 (31.0–185.0)
2 236 (34.9) 63.3 (29.3–172.0)
3+ 39 (5.8) 49.9 (19.5–105.0)
Sex
Males 336 (49.7) 60.1 (26.9–158.5)
Females 340 (50.3) 75.0 (33.2–196.0)
Age at follow-up*
Table 1 Distribution of maternal 1976 serum TCDD levels (ppt,
lipid-adjusted) by maternal and child-based characteristics;
SWHS, Italy, 1976–2016 (Continued)
N (%) N = 676
children of 438
mothers
1976 Serum TCDD
(ppt) Median (IQR)
2–13 161 (23.8) 166.0 (49.0–433.0)
14–22 167 (24.7) 66.2 (33.2–163.4)
23–30 171 (25.3) 60.0 (29.4–123.0)
31–39 177 (26.2) 40.7 (21.3–85.2)
Primary wage earner education at follow-up
Less than high school 200 (29.6) 65.3 (29.8–153.5)
High school 251 (37.1) 75.2 (33.3–247.0)
Greater than high school 225 (33.3) 60.0 (23.9–140.0)
aNumbers do not add to 100% because of missing data. 4 missing values for
maternal smoking during pregnancy
*p < 0.05 (ANOVA significant difference in log10TCDD by covariates)
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Seveso cohort [40, 43], and some studies measured a
mixture of PCBs, which also included non-dioxin-like
compounds [26], while others measured a combin-
ation of PCDDs, PCDFs, and other dioxin-like com-
pounds [26, 27, 30, 31].
The decreased risk of eczema can be explained by im-
munomodulatory effects of TCDD [52]. Although a de-
crease in eczema appears beneficial, the mechanisms
underlying this occurrence may be related to other
immunotoxic effects of TCDD, such as diminishing the
mobilization of immune cells or suppressing adaptive
immune responses, including some eczemas. The influ-
ence of TCDD on immunoregulation has been widely
proposed to be related to its interaction with the aryl
hydrocarbon receptor (AhR). TCDD is a potent AhR lig-
and, and its activation of the receptor alters many down-
stream signals that shape immune response. For
example, TCDD exposure may interfere with the balance
of regulatory T (Treg) cells and Type 1 (TH1) and Type
2 (TH2) helper T cells [52]. These cells influence other
immune cells’ response to antigens, such as initiating
the production of immunoglobulin E (IgE) antibodies
that cause allergic reactions. AhR-mediated responses
with TCDD may expand Treg and TH1 helper cell popu-
lations, while suppressing TH2 cell immune responses
[52, 53]. Another AhR-mediated mechanism by which
TCDD may impact eczema risk is by affecting the skin
barrier. In mice, in utero exposure to TCDD increased
epidermal barrier formation via activation of the AhR
[54] and increased expression of the filaggrin gene; a de-
ficiency and mutation in filaggrin has been associated
with eczema [55]. In vitro studies also show that TCDD
exposure accelerates keratinocyte differentiation [56].
Therefore, there may be an interplay of dermatological
and immunomodulatory responses from TCDD’s inter-
action with AhR, resulting in lower risk of eczema.
The immunomodulatory effects of prenatal and peri-
natal TCDD exposure have also been reported in animal
studies. For example, hematopoietic progenitor cells
from offspring of rodents exposed to TCDD had
Table 2 Adjusteda regression models of associations of maternal 1976 TCDD levels with atopic conditions in children, SWHS, Italy,
1976–2016
Adjusted RR (95% CI)
Outcomes Cases N (%) Total Male Female p-interaction
Eczema
Diagnosis and symptoms 98 (14.5) 0.93 (0.69, 1.27) 1.01 (0.72, 1.41) 0.86 (0.53, 1.37) 0.54
Diagnosis only 55 (8.2) 0.63 (0.40, 0.99) 0.64 (0.41, 0.99) 0.62 (0.29, 1.32) 0.96
Asthma
Diagnosis and symptoms 152 (22.5) 0.93 (0.71, 1.21) 0.90 (0.65, 1.24) 0.97 (0.66, 1.43) 0.72
Diagnosis only 81 (12.0) 0.93 (0.61, 1.40) 1.04 (0.65, 1.66) 0.77 (0.42, 1.40) 0.38
Hay fever
Diagnosis and symptoms 243 (36.0) 1.02 (0.86, 1.20) 0.91 (0.73, 1.13) 1.20 (0.95, 1.52) 0.07
Diagnosis only 130 (19.3) 0.99 (0.76, 1.27) 0.94 (0.67, 1.32) 1.04 (0.73, 1.49) 0.67
aModels adjusted for maternal age at explosion, atopic history, age at pregnancy, BMI closest to birth year, smoking during pregnancy, birth order, child sex, child
age, and primary wage earner education
Table 3 Adjusteda regression models for associations of TCDD estimated at pregnancy with child atopic conditions, SWHS, Italy,
1976–2016
Adjusted RR (95% CI)
Outcomes Cases N (%) Total Male Female p-interaction
Eczema
Diagnosis and symptoms 98 (14.5) 0.90 (0.60, 1.38) 0.86 (0.48, 1.53) 0.95 (0.60, 1.51) 0.75
Diagnosis only 55 (8.2) 0.71 (0.45, 1.12) 0.79 (0.46, 1.38) 0.61 (0.32, 1.19) 0.52
Asthma
Diagnosis and symptoms 152 (22.5) 0.93 (0.65, 1.34) 0.84 (0.54, 1.33) 1.07 (0.72, 1.60) 0.34
Diagnosis only 81 (12.0) 0.92 (0.52, 1.63) 0.77 (0.40, 1.45) 1.22 (0.62, 2.40) 0.21
Hay fever
Diagnosis and symptoms 243 (36.0) 1.09 (0.90, 1.31) 1.06 (0.84, 1.34) 1.13 (0.88, 1.45) 0.67
Diagnosis only 130 (19.3) 1.01 (0.75, 1.36) 0.96 (0.65, 1.41) 1.07 (0.72, 1.58) 0.67
aModels adjusted for maternal age at explosion, atopic history, age at pregnancy, BMI closest to birth year, smoking during pregnancy, birth order, child sex, child
age, and primary wage earner education
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decreased B and T-lymphocyte differentiation capacity,
compared to offspring of unexposed rats [17, 57]. In
mice, male offspring of dams exposed to TCDD during
both gestation and lactation exhibited a decrease in
spleen weights and interleukin-4 production of splenic
immune cells [33]. Another study of perinatally-exposed
rats reported similar findings of decreased thymus/body
weight ratio, delayed-type hypersensitivity response, and
percentage of splenic CD3+/CD4 −CD8− cells, which
are signs of attenuated cell-mediated immunity [18].
Furthermore, mice perinatally exposed to TCDD and
sensitized with injections of ovalbumin exhibited lower
serum levels of allergen-specific IgE, indicating that peri-
natal exposure to TCDD may lead to decreased allergic
sensitization [58].
An explanation for why we did not observe significant
associations in asthma or hay fever may be explained by
the natural history of atopic disorders, known as the
atopic march. Atopic march refers to the development
of atopic eczema and hypersensitivity to food or other
allergens in early childhood, and later progressing to
asthma and allergic rhinitis, or hay fever, in later life [1].
The majority of children in our sample were diagnosed
with the outcomes during childhood. However, age at
diagnosis was by maternal or self-report, which may not
be accurate. If age at diagnosis for eczema was under-
stated and the children were diagnosed with eczema
after asthma or hay fever, then there may be other
mechanisms underlying the null associations between
TCDD and the other atopic conditions. However, if in
utero exposure to TCDD did minimize the development
of eczema, this may have created a dent in the progres-
sion of the atopic march, and subsequent asthma and
hay fever may not be observed.
The significant association observed for initial TCDD
exposure and not TCDD estimated at pregnancy may in-
dicate that initial body burden at the time of exposure is
the relevant dose in impacting the children’s health out-
comes. TCDD exposure at the time of the accident may
have induced an epigenetic change in the women’s oo-
cytes, allowing for a transgenerational inheritance of dis-
ease outcomes [59, 60]. However, we still cannot rule
out that direct prenatal exposure at the time of preg-
nancy is also a relevant dose because our results for
TCDD exposure at pregnancy do show a tendency of de-
creased risk of eczema, and our study’s pregnancy-
TCDD levels were only estimated measurements.
Our results also show different significant associations
across the three outcomes based on the case definition
used. For example, we only observed a significant associ-
ation for eczema in the diagnosis-based case definition.
This may be due to misclassification in symptomatology,
and we observed a significant result because the
diagnosis-based case definition is more accurate and
specific than the one that also includes related symp-
toms. The opposite was true for hay fever, where we ob-
served a significant p-interaction value for the broader
case definition. This may be because hay fever is more
difficult to diagnose and people may not get it diagnosed
because of how common it occurs. Thus, using the
diagnosis-based case definition alone may have been less
sensitive and missed some cases. There are some limita-
tions to consider when interpreting these results. First,
we were not able to confirm outcomes with medical re-
cords and relied on maternal or child report, so there
may be outcome misclassification. However, we do not
expect there to be differential misclassification or re-
spondent bias because the interviewers and respondents
were unaware of the TCDD levels and study hypotheses.
Another limitation is potential residual confounding that
could have impacted our results. For example, we were
not able to control for the child’s delivery type because
of limited available data, and a cesarean delivery has
been shown to increase the risk of developing atopic dis-
eases [44]. Lastly, although we have an accurate measure
of initial TCDD levels, we estimated TCDD at preg-
nancy, which may lead to non-differential measurement
error for prenatal exposure. This misclassification would
bias our results towards the null because the degree of
exposure misclassification is not related to outcome sta-
tus; the same modeling approach was used to estimate
TCDD at pregnancy across all outcomes and so would
not explain the specific inverse finding with eczema.
This study has several strengths. First, it is a population-
based prospective cohort established based on residence
at the time of explosion, which allowed us to better assess
causality and measure multiple outcomes related to atopy
and immune functioning. To our knowledge, the SWHS
cohort represents the largest female TCDD-exposed popu-
lation with individual-level TCDD exposure data [36].
Also, because serum TCDD was obtained from blood
samples taken near the time of the accident, we have a dir-
ect measure of the individual’s exposure level as opposed
to other studies that have relied on indirect measures such
as maternal dietary levels [22, 23]. Therefore, we were able
to reduce exposure misclassification with biologic mea-
surements. Another advantage compared to other studies
is that exposure was predominantly to TCDD, whereas
other studies examined other dioxin-like compounds in-
cluding PCDD, PCDF, and dioxin-like PCBs. In our study,
levels of other dioxin-like compounds were not elevated
above background levels although 1976 background levels
were high, compared to more recent studies [42].
Conclusions
In summary, we found that maternal serum TCDD
levels near the time of explosion were associated with
lower risk of eczema but there was no relationship with
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asthma or hay fever among children of the SWHS sec-
ond generation cohort. The results are consistent with
the dysregulated immune effects of TCDD observed in
both animals and human studies, and support other evi-
dence suggesting that prenatal TCDD exposure may in-
crease the development of infectious diseases and
decrease allergic conditions. With continued follow-up
of SWHS children using antibody titer data and more
accurate measurements of TCDD at pregnancy, we will
begin to better elucidate mechanisms underlying these
findings.
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